$7.20
509.33% yesterday
Nasdaq, Jun 13, 10:15 pm CET
ISIN
US04301G2012
Symbol
ARTL

Artelo Biosciences Inc Stock price

$7.20
+1.02 16.42% 1M
+0.54 8.03% 6M
+0.84 13.13% YTD
-0.79 9.84% 1Y
-106.21 93.66% 5Y
-0.81 10.06% 10Y
-0.81 10.06% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.11 1.56%
ISIN
US04301G2012
Symbol
ARTL

Key metrics

Market capitalization $23.25m
Enterprise Value $22.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 36.21
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-9.90m
Free Cash Flow (TTM) Free Cash Flow $-7.01m
Cash position $750.00k
EPS (TTM) EPS $-2.96
P/E forward negative
Short interest 5.92%
Show more

Is Artelo Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Artelo Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Artelo Biosciences Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Artelo Biosciences Inc:

Hold
100%

Financial data from Artelo Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.03 4.03
5% 5%
-
- Research and Development Expense 5.87 5.87
2% 2%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.90 -9.90
3% 3%
-
Net Profit -9.71 -9.71
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Artelo Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Artelo Biosciences Inc Stock News

Neutral
GlobeNewsWire
3 days ago
SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo's Board of Directors approved a 6-for-1 reverse stock split (“Rever...
Neutral
GlobeNewsWire
9 days ago
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June ...
Neutral
GlobeNewsWire
12 days ago
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled “Fatty acid binding...
More Artelo Biosciences Inc News

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Head office United States
CEO Gregory Gorgas
Employees 6
Founded 2011
Website artelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today